Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Covidien Receives FDA Approval for Morphine Sulfate Oral Solution

By Pharmaceutical Processing | August 1, 2011

 

Covidien today announced that the FDA recently granted
approval to the company’s Mallinckrodt business for morphine sulfate oral solution,
used to relieve moderate to severe acute and chronic pain in opioid-tolerant
patients. The solution will be available as a generic in 100 milligrams per 5
mL (20 milligrams per 1 mL).

“FDA approval of this drug represents a key component
in palliative care treatment,” said Matthew Harbaugh, Chief Financial
Officer and Interim President, Pharmaceuticals, Covidien. “It is important
that we are able to respond to the concerns of the hospice and palliative care community.”
Morphine sulfate oral solution has been used to manage pain for many years, and
Mallinckrodt began marketing the 20 milligram per 1 mL strength in 2005. Prior
to 2010, however, this form and concentration of morphine had never been
approved by the FDA.

In April, 2009, the FDA announced that manufacturers could
keep morphine sulfate oral solution on the market, but only until the product
was approved, or an equivalent, approved therapy was available. Accordingly,
upon approval of a new drug application (NDA) by another manufacturer in
January 2010, Mallinckrodt removed its product from the market. Mallinckrodt
undertook the current approval process to ensure adequate supply of this
medication to patients.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE